AbbVie

News

Allergan, Teva considering $5bn play to shake off opioid han...

AbbVie's Allergan subsidiary and Teva are reportedly considering making a $5 billion-plus offer to try to bring opioid liability lawsuits to a conclusion.

News

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Pfizer's $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug.

News

x-ray image of human head with brain and electric pulses

BioArctic left in the cold as AbbVie abandons Parkinson's pa...

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson's disease – AbbVie – is ducking out of the challenge.

News

Genmab and AbbVie prep filings for lymphoma bispecific

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead dr

News

AACR: AbbVie says mid-stage trial backs navitoclax in myelof...

AbbVie's BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with Venclexta, i

News

AbbVie sees bigger role for Qulipta in migraine prevention

AbbVie's Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting it up for a role in a category curren

Allergan, Teva considering $5bn play to shake off opioid han...

Pfizer/Biohaven migraine drug rimegepant gets EU green light

BioArctic left in the cold as AbbVie abandons Parkinson's pa...

Genmab and AbbVie prep filings for lymphoma bispecific

AACR: AbbVie says mid-stage trial backs navitoclax in myelof...

AbbVie sees bigger role for Qulipta in migraine prevention

Novo Nordisk fight with KBP Bio will go to arbitration

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks